MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $10.66M rose 183.7% year over year, ahead of the +164.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 43.2% from the prior quarter. Over 3 fiscal years it compounded at +95.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +113.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.66M-43.2% QoQ
- Last fiscal yearDec 2025
- $30.73M+113.1% YoY
- LTMMar 2026
- $37.63M+164.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +183.7% | -100.0% | -283.7 pp |
| 1 year | +113.1% | -100.0% | -213.1 pp |
| 3-year CAGR | +95.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 30.73M USD
- Year-over-year change
- +113.1%
- 3-year CAGR
- +95.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.73M | +113.1% |
| FY2024 | 2024-12-31 | 14.42M | +89.6% |
| FY2023 | 2023-12-31 | 7.61M | +85.5% |
| FY2022 | 2022-12-31 | 4.1M | — |
Selling, General & Admin vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 selling, general & admin of $37.63M is the 5th highest of the 11 companies compared; the peer median is $29.51M.
- Its year-over-year change of +164.2% is the 2nd highest of 10, against a peer median of +22.3%.
- Over three fiscal years its annual growth of +95.7% compares with a peer median of +26.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.42B | +118480.6% | -4.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $84.34M | +86.2% | +17.3% | — |
| LTM Mar 2026 | $78.85M | +22.3% | +72.8% | 64.5% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $37.63M | +164.2% | +95.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $24.75M | -6.4% | -9.4% | 347.5% | |
| LTM Mar 2026 | $23.07M | +35.6% | +29.0% | — | |
| LTM Mar 2026 | $21.89M | -3.6% | +59.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
| LTM Dec 2025 | $12.8M | +10.2% | +1.9% | — | |
| Peer median (excluding MPLT) | $29.51M | +22.3% | +26.8% | 171.4% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 574K | 556K | 701K | 578K |
| Gross Profit | (574K) | (556K) | (701K) | (578K) |
| Gross Margin | — | — | — | — |
| Research & Development | 26.57M | 49.12M | 67.82M | 137.77M |
| Selling, General & Admin | 4.1M | 7.61M | 14.42M | 30.73M |
| Operating Expenses | 30.67M | 56.73M | 82.25M | 168.51M |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| EBITDA | (29.44M) | (55.15M) | (76.88M) | (160.57M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (31.25M) | (57.28M) | (82.95M) | (169.08M) |
| Operating Margin | — | — | — | — |
| Interest Income | 429K | 1.1M | 4.5M | 5.52M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.23M | 1.57M | 5.37M | 7.93M |
| Income Before Tax | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.72) | (1.34) | (1.87) | (3.66) |
| EPS (Diluted) | (0.72) | (1.34) | (1.87) | (3.66) |
| Weighted Avg Shares | 41.43M | 41.43M | 41.43M | 44.02M |
| Weighted Avg Shares (Diluted) | 41.43M | 41.43M | 41.43M | 44.02M |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.